Healthcare Services

Gastrointestinal Cancer Market Industry Forecast Reflecting Growth To $47.4 Billion By 2030

May 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Gastrointestinal Cancer Market During 2026–2030?

The gastrointestinal cancer market has expanded swiftly in recent years. It is anticipated to increase from $27.05 billion in 2025 to $30.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.1%. This historic growth can be attributed to the increasing prevalence of gastrointestinal cancers, the expansion of diagnostic imaging capabilities, rising awareness of early cancer detection, growth in oncology drug development, and improved access to cancer treatment facilities.

The gastrointestinal cancer market is projected for significant expansion in the coming years, anticipated to reach a valuation of $47.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This growth over the forecast period can be attributed to increasing investments in personalized oncology, the growing adoption of biomarker-based diagnostics, the expansion of immuno-oncology pipelines, the rising use of minimally invasive diagnostics, and an increase in healthcare spending for cancer care. Key trends anticipated during this period encompass the increased adoption of targeted gastrointestinal cancer therapies, the growing application of molecular diagnostics, a greater emphasis on immunotherapy combinations, the expansion of early cancer screening initiatives, and enhanced integration of precision medicine.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

What Core Drivers Are Transforming The Gastrointestinal Cancer Market?

The increasing acceptance of targeted therapies is anticipated to stimulate future expansion in the gastrointestinal cancer market. These treatments precisely inhibit cancer cell proliferation by acting on specific molecular targets, thereby minimizing damage to normal, healthy cells. Targeted therapies are specifically designed to interact with particular molecular pathways or genetic mutations that drive a disease, especially within cancer. Unlike traditional treatments such as chemotherapy, which indiscriminately attack both healthy and diseased cells, targeted therapies concentrate on the unique characteristics of a patient’s condition. For gastrointestinal (GI) cancer, these therapies function by targeting specific genes or proteins that control tumor growth, leading to precise and effective treatment. This results in superior outcomes with fewer adverse effects than conventional chemotherapy. For instance, in July 2023, as per the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II at the end of quarter one (Q1) 2023, with this total increasing by 5% to reach 260 by the end of quarter two (Q2). Consequently, the growing integration of targeted therapies is actively fueling the expansion of the gastrointestinal cancer market.

How Is The Gastrointestinal Cancer Market Structured Across Different Market Segments?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

What Trends Are Shaping The Gastrointestinal Cancer Market Structure?

Leading companies within the gastrointestinal cancer market are concentrating on creating sophisticated solutions, including monoclonal antibody treatment, with the aim of boosting patient survival rates and lessening adverse effects associated with treatment. Monoclonal antibody treatment functions by utilizing antibodies produced in laboratories that accurately pinpoint and attach to cancer cells, thereby aiding the immune system in identifying and eradicating them. As an illustration, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical firm, introduced VYLOY (zolbetuximab) when combined with fluoropyrimidine- and platinum-containing chemotherapy, after receiving authorization from the European Commission. This therapy serves as a first-line option for adults diagnosed with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, specifically those whose tumors display claudin 18.2 (CLDN18.2) expression. The aforementioned approval positions VYLOY as the initial and exclusive treatment in the European Union targeting CLDN18.2, a biomarker present in approximately 38% of these patients, a finding substantiated by positive outcomes from the SPOTLIGHT and GLOW clinical trials.

Which Organizations Are Operating Within The Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Access The Complete Gastrointestinal Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Region Accounts For The Highest Share Of The Gastrointestinal Cancer Market?

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gastrointestinal Cancer Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2026, By The Business Research Company

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Gastroparesis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Barretts Esophagus Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/barretts-esophagus-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795